Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $31.8 million.

  • Myriad Genetics' Accounts Payables rose 743.24% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 743.24%. This contributed to the annual value of $32.3 million for FY2024, which is 2519.38% up from last year.
  • Per Myriad Genetics' latest filing, its Accounts Payables stood at $31.8 million for Q3 2025, which was up 743.24% from $30.9 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Accounts Payables high stood at $39.8 million for Q2 2023, and its period low was $15.7 million during Q3 2021.
  • Moreover, its 5-year median value for Accounts Payables was $29.6 million (2021), whereas its average is $29.3 million.
  • In the last 5 years, Myriad Genetics' Accounts Payables plummeted by 3135.31% in 2021 and then surged by 8853.5% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Accounts Payables stood at $29.6 million in 2021, then decreased by 2.7% to $28.8 million in 2022, then decreased by 10.42% to $25.8 million in 2023, then increased by 25.19% to $32.3 million in 2024, then decreased by 1.55% to $31.8 million in 2025.
  • Its Accounts Payables stands at $31.8 million for Q3 2025, versus $30.9 million for Q2 2025 and $28.1 million for Q1 2025.